Lexicon Pharmaceutcl (LXRX) Stock Price, Quote & News

Company Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its...

Industry: Biotechnology

Sector: Healthcare

Phone: 281 863 3000

Fax: 281 863 8088

Website: www.lexpharma.com

Address:

2445 Technology Forest Boulevard, 11th Floor, The Woodlands, United States

UofMAlum Mar. 17 at 7:57 PM

$LXRX how does Stocktwits determine bullish or bearish. I keep posting bullish in an effort to move the needle positive.

1 · Reply

UofMAlum Mar. 17 at 5:50 PM

$LXRX

0 · Reply

Anon_ymous1 Mar. 17 at 3:15 PM

$LXRX 11 months ago, somehow missed this. https://www.linkedin.com/posts/don-valley-pharmaceuticals_donvalleypharma-donvalley-madeinpakistan-activity-7318931769355845632-v6Mm Digged a bit more and it will be sold in Kenya as an adjunct to insulin for Type 1 diabetes patients actually and not for heart failure. https://products.pharmacyboardkenya.org/uploads/CTD10499_SEIZ_TABLETS_SMPC.pdf

1 · Reply

gucag006 Mar. 17 at 2:02 PM

$LXRX AI/SI and your survival in the "intelligence" jungle.

0 · Reply

gucag006 Mar. 17 at 10:16 AM

$LXRX From Gemini Pro on Pilavapadin partnership talks:

1 · Reply

atreus57 Mar. 17 at 5:39 AM

$LXRX moving towards $7 very soon...

2 · Reply

Dooright Mar. 17 at 1:06 AM

$LXRX No reason. Just this whacky stock and its unrelenting manipulation. It’s all good! 😜 Doc C. 🤓

1 · Reply

Jas7235355 Mar. 16 at 11:38 PM

$LXRX You don’t have a vote anymore.RD holds all the cards now. All of OUR votes cannot override his!

0 · Reply

Ruggle Mar. 16 at 10:37 PM

$LXRX Not worried about the share authorization increasing to 900M. Considering the cash they already have before all the upcoming catalysts, you’d think a raise wouldn’t even be necessary. I’d rather they increase it to 900M now than go from 600M to 900M later and trigger another negative headline that pushes the price down again in the short term.

0 · Reply

LionNoRichy Mar. 16 at 9:57 PM

$LXRX didn't follow the last 3 days, why are we down

0 · Reply

Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes

Mar 5, 2026, 5:15 PM EST - 12 days ago

Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2025 Earnings Call Transcript

Mar 5, 2026, 6:59 AM EST - 12 days ago

Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates

Mar 3, 2026, 4:01 PM EST - 14 days ago

Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences

Feb 26, 2026, 8:30 AM EST - 19 days ago

Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026

Feb 6, 2026, 5:17 PM EST - 5 weeks ago

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

Jan 30, 2026, 2:50 AM EST - 6 weeks ago

Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

Jan 29, 2026, 4:31 PM EST - 6 weeks ago

Lexicon Announces Proposed Public Offering of Common Stock

Jan 23, 2026, 8:30 AM EST - 7 weeks ago

Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary

Jan 21, 2026, 8:30 AM EST - 7 weeks ago

Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain

Jan 20, 2026, 6:59 AM EST - 2 months ago

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

VTRS

Jan 15, 2026, 5:26 PM EST - 2 months ago

Lexicon Pharmaceuticals, Inc. (LXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 7:30 AM EST - 2 months ago

Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference

Jan 9, 2026, 8:30 AM EST - 2 months ago

Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”

Jan 7, 2026, 8:30 AM EST - 2 months ago

Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 10, 2025, 8:30 AM EST - 3 months ago

Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851

Dec 5, 2025, 8:30 AM EST - 3 months ago

Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum

Dec 3, 2025, 10:30 AM EST - 3 months ago

Lexicon Pharmaceuticals Has Multiple Paths To Upside, But Formidable Hurdles As Well

Nov 25, 2025, 8:30 AM EST - 4 months ago

Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences

Nov 19, 2025, 3:53 PM EST - 4 months ago

Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 15, 2025, 6:46 AM EST - 4 months ago

Lexicon Pharmaceuticals: A Lottery Ticket With 3 Chances To Win

Nov 11, 2025, 8:30 AM EST - 4 months ago

Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference

Nov 8, 2025, 2:30 PM EST - 4 months ago

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

Nov 6, 2025, 2:16 PM EST - 4 months ago

Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 7:30 AM EST - 4 months ago

Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates

Nov 4, 2025, 8:30 AM EST - 4 months ago

Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association's Sessions 2025 in New Orleans

Oct 30, 2025, 8:30 AM EDT - 4 months ago

Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 14, 2025, 8:00 AM EDT - 5 months ago

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit

Oct 8, 2025, 7:59 AM EDT - 5 months ago

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain

Sep 22, 2025, 4:00 PM EDT - 6 months ago

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Sep 17, 2025, 7:00 AM EDT - 6 months ago

Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings

Sep 11, 2025, 8:30 AM EDT - 6 months ago

Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings

Sep 8, 2025, 8:30 AM EDT - 6 months ago

Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Sep 4, 2025, 8:30 AM EDT - 6 months ago

Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025

Sep 3, 2025, 7:36 PM EDT - 6 months ago

Lexicon Pharmaceuticals, Inc. (LXRX) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 3, 2025, 8:30 AM EDT - 6 months ago

Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025

Sep 2, 2025, 8:30 AM EDT - 7 months ago

Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress

Aug 27, 2025, 8:30 AM EDT - 7 months ago

Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences

Aug 6, 2025, 12:39 PM EDT - 7 months ago

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 7:30 AM EDT - 7 months ago

Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 31, 2025, 8:00 AM EDT - 8 months ago

Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 23, 2025, 8:00 AM EDT - 8 months ago

Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 18, 2025, 8:00 AM EDT - 8 months ago

Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)

Jun 23, 2025, 8:00 AM EDT - 9 months ago

Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Jun 18, 2025, 8:30 AM EDT - 9 months ago

Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)

May 29, 2025, 8:00 AM EDT - 10 months ago

Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 19, 2025, 8:00 AM EDT - 10 months ago

SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology

May 13, 2025, 9:47 PM EDT - 11 months ago

Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:00 PM EDT - 11 months ago

Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates

May 6, 2025, 4:30 PM EDT - 11 months ago

Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

UofMAlum Mar. 17 at 7:57 PM

$LXRX how does Stocktwits determine bullish or bearish. I keep posting bullish in an effort to move the needle positive.

1 · Reply

UofMAlum Mar. 17 at 5:50 PM

$LXRX

0 · Reply

Anon_ymous1 Mar. 17 at 3:15 PM

1 · Reply

gucag006 Mar. 17 at 2:02 PM

$LXRX AI/SI and your survival in the "intelligence" jungle.

0 · Reply

gucag006 Mar. 17 at 10:16 AM

$LXRX From Gemini Pro on Pilavapadin partnership talks:

1 · Reply

atreus57 Mar. 17 at 5:39 AM

$LXRX moving towards $7 very soon...

2 · Reply

Dooright Mar. 17 at 1:06 AM

$LXRX No reason. Just this whacky stock and its unrelenting manipulation. It’s all good! 😜 Doc C. 🤓

1 · Reply

Jas7235355 Mar. 16 at 11:38 PM

$LXRX You don’t have a vote anymore.RD holds all the cards now. All of OUR votes cannot override his!

0 · Reply

Ruggle Mar. 16 at 10:37 PM

0 · Reply

LionNoRichy Mar. 16 at 9:57 PM

$LXRX didn't follow the last 3 days, why are we down

0 · Reply

popeyecallings Mar. 16 at 9:41 PM

$LXRX so are we voting yay to increase shares to 900 milli ? 🫣🥹

2 · Reply

UofMAlum Mar. 16 at 9:39 PM

$LXRX My initial career was as a CPA, but about 15 years ago I changed careers and now work as an RN. I got in this stock about 1 year ago, because a coworker pointed it out to me. Because of my new career as an RN, and my experience in finance, I recognized what the value of a non-opiod pain medication could bring, and bought in heavy into this stock. I can honestly tell everyone I haven't looked back, and have not been disappointed in the performance. New drugs take time, but if Pilavapadin turns out to be the real deal, we will be rewarded heavily for our patience.

0 · Reply

Hightower777 Mar. 16 at 8:05 PM

$LXRX I wonder if the overlords who control this stock price will pull it back under $1.50 again so they can print more options profits? All as we await Mr. Exton’s long promised partnership(s) …

2 · Reply

Dooright Mar. 16 at 8:04 PM

$LXRX Puré manipulation and an attempt to steal retail shares. Just relax and enjoy the ride this year! It’s all good. Very, very good! AMHO. Doc C. 🤓

1 · Reply

copper2millies Mar. 16 at 7:35 PM

$LXRX Not going to lie, it is hard to own this stock. Not mad, just hard to own. You think you are on a roll and then you have days like this for no reason at all.

1 · Reply

macrossluvsrobotech Mar. 16 at 5:36 PM

$LXRX

0 · Reply

humble_bob Mar. 16 at 5:08 PM

$LXRX Never sees $2 again

1 · Reply

ABDeb Mar. 16 at 4:23 PM

$LXRX the entire market is green and this stock despite so many backlog still struggling

0 · Reply

Anon_ymous1 Mar. 16 at 3:56 PM

$LXRX Zynquista resubmission or Pilavapdin partnerships, whats comes first fellas? I hope its Pilavapadin.

2 · Reply

DojiSTR Mar. 16 at 3:26 PM

$LXRX cant stay green in this market is criminal.

0 · Reply

Daywalker777 Mar. 16 at 3:25 PM

$LXRX ahhh the markets are surging…that means we have to go down, 😭

0 · Reply

Mister_Bungle Mar. 16 at 2:50 PM

$LXRX how many years before this goes above $2? I feel like I've been holding this stock for most of my life

0 · Reply

Market Cap	716.02M
Revenue (ttm)	49.80M
Net Income (ttm)	-50.34M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-101.08%
Debt to Equity Ratio	0.50

Volume	1,307,700
Avg Vol	2,982,264
Day's Range	N/A - N/A
Shares Out	423.68M
Stochastic %K	50%
Beta	0.94
Analysts	Sell
Price Target	$3.36